A carregar...
How can we achieve universal access to low-cost treatment for HIV?
Mass production of low-cost antiretrovirals (ARVs) has already allowed over 17 million individuals to access treatment for HIV infection, mainly in low-income countries. It is possible to manufacture combination ARVs for $110 per person-year, using tenofovir (TDF), lamivudine (3TC) and efavirenz (EF...
Na minha lista:
| Publicado no: | J Virus Erad |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Mediscript Ltd
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5075345/ https://ncbi.nlm.nih.gov/pubmed/27781100 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|